Regeneron Pharmaceuticals, Inc. (REGN)
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy
Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Regeneron says it expects to avoid new US pharma tariffs
Drugmaker Regeneron said on Thursday it expects to be excluded from a list of pharmaceutical companies that could face new tariffs from the U.S. government.
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?
Regeneron's rally reflects biotech momentum as pipeline wins and Dupixent growth offset Eylea erosion amid intensifying competition.
Alliancebernstein L.P. Sells 63,344 Shares of Regeneron Pharmaceuticals, Inc. $REGN
Alliancebernstein L.P. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 10.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 523,883 shares of the biopharmaceutical company's stock after selling 63,344 shares during the period. Alliancebernstein L.P. owned
Game Creek Capital LP Has $2.77 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
Game Creek Capital LP boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 60.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,925 shares of the biopharmaceutical company's stock after acquiring an additional 1,850 shares
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-six analysts that are presently covering the company, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and two have assigned a strong buy
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
Regeneron: Fairly Valued Now After A Stellar Upswing
Regeneron Pharmaceuticals, Inc. is rated a long-term Buy, but I expect near-term sideways trading due to limited new catalysts. Declining Eylea/Eylea HD revenues are largely offset by strong Dupixent growth, with Dupixent likely to exceed 50% of total revenue by 2027. Libtayo and pipeline assets show promise, but meaningful revenue impact is expected only after 2026; diversification into new areas brings both opportunity and capital allocation risk.
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
